Spain's Oryzon Bucks Trend To Seek NASDAQ Listing
While Raising Cash For Cancer and CNS Drugs
The year to date has been a depressing period for initial public offerings, especially in Europe, but the Madrid-based epigenetics specialist is evaluating whether to head west and list in the US.
You may also be interested in...
CEO Pierre Belichard tells Scrip that the French biotech has enough cash and assets to prosper alone but it is also weighing up a reverse merger that would give Enterome a listing on the NASDAQ.
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
A market leader in opioid addiction, Indivior is expanding into the cannabis abuse space which is increasing exponentially due to widespread legalization of recreational use for the drug.